Skip to main content

Table 4 Correlation analysis of the factors associated with urinary glucose on day 7 of treatment with SGLT2 inhibitors

From: Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring

  Urinary glucose p value
MBG 0.414* 0.050
SD −0.209 0.337
CV −0.305 0.157
Time at >140 mg/dL 0.468* 0.024
Time at <70 mg/dL −0.228 0.298
Time at 70–140 mg/dL −0.470* 0.023
MAGE 0.135 0.539
LAGE −0.381 0.073
M value 0.303 0.159
MPPGE −0.093 0.673
Max 0.012 0.955
Min 0.474* 0.022
  1. Data are results of Pearson correlation analysis of variables with normal distribution (MBG, CV and Max) and Spearman rank correlation for variables with skewed distribution
  2. IRI immunoreactive insulin, HbA1c glycated hemoglobin, CPR C peptide immunoreactivity, eGFR estimated glomerular filtration rate, CGM continuous glucose monitoring, SGLT2-I sodium glucose cotransporter 2 inhibitor, MBG mean blood glucose, SD standard deviation, CV coefficient of variation, MAGE mean amplitude of glycemic excursions, LAGE largest amplitude of glycemic excursions, MPPGE mean postprandial glucose excursions, BG blood glucose, BB before breakfast, AB after breakfast, BL before lunch, AL after lunch, BD before dinner, AD after dinner
  3. * p < 0.05